Skip to content

Nature of phonatory disorders and efficacy of voice therapy in older adults with sarcopenia

Nature of phonatory disorders and efficacy of voice therapy in older adults with sarcopenia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127233
Enrollment
Unknown
Registered
2026-06-26
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia in older adults, Voice Disorders

Interventions

Control group 1 (older adults with sarcopenia with voice disorders):Vocal hygiene education
Experimental group (older adults with sarcopenia with voice disorders):Semi-occluded vocal tract exercise (SOVT), straw phonation in water exercise (SPW), and vocal hygiene education
Control group 2 (older adults with sarcopenia with normal voice):None

Sponsors

The Second Affiliated Hospital, Xiamen Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Older adults (60 years old or above, according to the World Health Organization); 2. Formal diagnosis of sarcopenia according to the Asian Working Group for Sarcopenia (AWGS) 2019 Consensus Update on Sarcopenia Diagnosis and Treatment; 3. Cognitive function capable of conducting vocal assessment and voice therapy; 4. Informed consent to voluntarily participate in research.

Exclusion criteria

Exclusion criteria: 1. Centenarians (aged at or above 100); 2. Absolute bed rest (of 5 days or more) in the past 6 months, according to the European Working Group on Sarcopenia in Older People 2(EWGSOP2)2019 revised European consensus on definition and diagnosis; 3. Confirmed ENT diagnosis of laryngopharyngeal reflux (LPR); 4. History of laryngeal or head and neck diseases or surgery; 5. History of vocal training; 6. History of voice therapy; 7. History of severe heart, brain, lung, liver, kidney, or neurological diseases, malignancy, cachexia; 8. Taking medications causing severe loss of appetite.

Design outcomes

Primary

MeasureTime frame
Laryngeal endoscopic assessment of normalized glottal gap area (NGGA);Voice quality assessment using CAPE-V (overall severity, roughness, breathiness, strain, pitch, loudness);Acoustic parameter (fundamental frequency);Acoustic parameter (intensity);Acoustic parameter (jitter);Acoustic parameter (shimmer);Acoustic parameter (harmonics-to-noise ratio);Acoustic parameter (smoothed cepstral peak prominence);Aerodynamic parameter (mean flow rate);Aerodynamic parameter (phonation threshold flow);Aerodynamic parameter (subglottal pressure);Aerodynamic parameter (phonation threshold pressure);Aerodynamic parameter (laryngeal airway resistance);

Secondary

MeasureTime frame
Voice-Related Quality of Life (V-RQOL);Vocal Fatigue Index (VFI);Aging Voice Index (AVI);Lung function parameter (vital capacity, VC);Lung function parameter (forced expiratory volume in one second, FEV1);Lung function parameter (forced vital capacity, FVC);Lung function parameter (FEV1/FVC);Lung function parameter (peak expiratory flow, PEF);Lung function parameter (maximum mid-expiratory flow, MMEF);

Countries

China

Contacts

Public ContactJunhu Tai / Roger W. Chan

The Second Affiliated Hospital, Xiamen Medical College

junhu69@126.com+86 159 0433 6911

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026